MoonLake CSO-linked entity sells 16,105 shares

Rhea-AI Filing Summary

MoonLake Immunotherapeutics Chief Scientific Officer Kristian Reich reported an indirect sale by JeruCON Beratungsgesellschaft mbH of 16,105 Class A shares on July 15, 2026 under a Rule 10b5-1 trading plan adopted March 10, 2026 at a weighted average price of $20.01 per share, with individual trades from $20.00 to $20.04.

After the sale, JeruCON remained the indirect holder of 2,808,446 Class A ordinary shares, while Reich directly held 35,389 Class A shares.

Insider Trade Summary 10b5-1

Net Seller: 16,105 shares

Net Sell 2 txns

Insider Reich Kristian

Role Chief Scientific Officer

Sold 16,105 shs ($322K)

Type	Security	Shares	Price	Value
Sale	Class A ordinary shares, par value $0.0001 per share F1, F2, F3	16,105	$20.01	$322K
holding	Class A ordinary shares, par value $0.0001 per share	--	--	--

Holdings After Transaction: Class A ordinary shares, par value $0.0001 per share — 2,808,446 shares (Indirect, See footnote.); Class A ordinary shares, par value $0.0001 per share — 35,389 shares (Direct)

Footnotes (3)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.
2. F2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.04. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3. F3. Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

Key Figures

Shares sold: 16,105 shares Weighted average sale price: $20.01 per share Indirect holdings after sale: 2,808,446 shares +2 more

5 metrics

Shares sold 16,105 shares Class A ordinary shares sold on July 15, 2026 by JeruCON Beratungsgesellschaft mbH

Weighted average sale price $20.01 per share Weighted average price, with trades from $20.00 to $20.04

Indirect holdings after sale 2,808,446 shares Class A ordinary shares indirectly owned through JeruCON after the July 15, 2026 sale

Direct holdings 35,389 shares Class A ordinary shares held directly by Kristian Reich as of July 15, 2026

Rule 10b5-1 plan adoption date March 10, 2026 Date the trading plan governing the reported sale was adopted

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, indirect beneficial owner, Section 16

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported represents the weighted average sale price per share for the multiple transactions."

indirect beneficial owner regulatory

"may be deemed to be the indirect beneficial owner of the ordinary shares owned by JeruCON."

Section 16 regulatory

"for purposes of Section 16 of the Securities Exchange Act of 1934, as amended."

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share sale did MoonLake Immunotherapeutics (MLTX) report for Kristian Reich?

MoonLake Immunotherapeutics reported that Chief Scientific Officer Kristian Reich, through JeruCON Beratungsgesellschaft mbH, sold 16,105 Class A shares on July 15, 2026. The sale was executed under a Rule 10b5-1 trading plan at a weighted average price of $20.01 per share.

How many MoonLake (MLTX) shares does Kristian Reich own after the reported transactions?

After the reported sale, JeruCON Beratungsgesellschaft mbH held 2,808,446 MoonLake Class A ordinary shares indirectly attributable to Kristian Reich for Section 16 purposes. Separately, Reich directly owned 35,389 Class A shares as of July 15, 2026.

At what price were the MLTX shares sold in this insider transaction?

The sale was reported at a weighted average price of $20.01 per share. Footnotes state the 16,105 shares were sold in multiple trades at prices ranging from $20.00 to $20.04, and detailed trade breakdowns are available upon request.

Was the MoonLake (MLTX) insider sale under a Rule 10b5-1 trading plan?

Yes. A footnote explains that the July 15, 2026 sale of 16,105 MoonLake Class A shares was executed under a Rule 10b5-1 trading plan adopted on March 10, 2026, indicating the trades were pre-arranged rather than discretionary.

Who actually holds the MoonLake (MLTX) shares involved in the sale?

The 16,105 shares sold, and the remaining 2,808,446 indirectly held shares, belong to JeruCON Beratungsgesellschaft mbH. Footnotes state that Kristian Reich may be deemed an indirect beneficial owner of JeruCON’s MoonLake ordinary shares for Section 16 purposes.

Does Kristian Reich’s latest MoonLake (MLTX) Form 4 report any derivative securities?

No. Only one non-derivative transaction is shown: a sale of 16,105 Class A ordinary shares associated with JeruCON. No options, warrants, or other derivative securities are included in the reported transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/20/2026 - 06:07 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reich Kristian

(Last) (First) (Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG 6300

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A ordinary shares, par value $0.0001 per share	07/15/2026		S(1)		16,105	D	$20.01(2)	2,808,446	I	See footnote.(3)
Class A ordinary shares, par value $0.0001 per share								35,389	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.04. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

	/s/ Matthias Bodenstedt, Attorney-in-fact for Kristian Reich	07/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)